Roche has been working with US AI specialist PathAI for around five years, and has now upgraded that partnership with an offer to buy the company outright for $1.05 billion. Already a giant in the ...

In his many public events announcing these MFN deals and in his State of the Union, President Trump has repeated the same ...

The Pharma Specialized Network (PSN) provides a globally integrated solution for delivering end-to-end distribution to ...

The evolving role of early-phase clinical trials reflects a broader truth: decisions made early carry increasing weight in ...

To understand the key trends and client conversations that shaped this year's summit, pharmaphorum sat down with Krista Pinto ...

Across events and general day-to-day industry updates, one term has dominated market access conversations in 2026: Most ...

Italy's Angelini Pharma has agreed to buy Catalyst Pharma of the US for up to $4.1 billion, saying the deal is a "pivotal moment" in its 100-year-plus history. Privately held Angelini will pay $31.50 ...

EVERSANA has named Mike Guarino to lead its global health agency EVERSANA INTOUCH, which was formed in 2022 by the merger of ...

Bristol Myers Squibb has reached for its wallet to avoid being left behind in the race to develop a new class of bispecific antibodies for cancer that have been billed as the next big thing in ...

Bristol Myers Squibb and Pfizer have launched an online programme to sell their blockbuster anticoagulant Eliquis directly to patients, following in the footsteps of Eli Lilly and Novo Nordisk in a ...

RNA interference drug developer SanegeneBio leads our round-up of this week's biotech financings, with a $110 million Series B backed by recent partner Eli Lilly. SanegeneBio, a biotech company with ...

Indian pharma group Wockhardt has completed a pre-filing meeting with the FDA and hopes to submit its new antibiotic Zaynich in the US and Europe later this year, eyeing a possible launch in fiscal ...